"10.1371_journal.pone.0051313","plos one","2012-12-13T00:00:00Z","Martina Kalle; Praveen Papareddy; Gopinath Kasetty; Matthias Mörgelin; Mariena J A van der Plas; Victoria Rydengård; Martin Malmsten; Barbara Albiger; Artur Schmidtchen","Division of Dermatology and Venereology, Department of Clinical Sciences, Biomedical Center, Lund University, Lund, Sweden; Division of Infection Medicine, Department of Clinical Sciences, Biomedical Center, Lund University, Lund, Sweden; Department of Pharmacy, Uppsala University, Uppsala, Sweden; Medeon Science Park, Malmö, Sweden; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden","Conceived and designed the experiments: BA AS. Performed the experiments: MK PP GK MJAvdP VR M. Mörgelin. Analyzed the data: MK. Contributed reagents/materials/analysis tools: M. Malmsten M. Mörgelin. Wrote the paper: MK AS.","Dr. Schmidtchen owns shares in Xmedic AB, a company that develops thrombin-derived peptides for human therapy. Parts of the in vivo work were initially sponsored by XImmune AB according to a research agreement with Lund University. XImmune AB has however transferred all IP rights concerning thrombin-derived host defense peptides to Xmedic AB. This does not alter the authors adherence to all PLOS One policies on sharing data and materials.","2012","12","Martina Kalle","MK",9,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
